MGRX:NASDAQMangoceuticals, Inc. Analysis

Mangoceuticals trades at $0.44, well below its DCF fair value of $1.49, indicating a potential valuation gap. However, the stock is highly volatile (148% 30‑day volatility) and beta‑adjusted risk is elevated (beta ~2.1), reflecting sensitivity to market swings. Technicals show price above the 20‑day and 50‑day SMAs (0.38) but far under the 200‑day SMA (1.13), signaling a bearish long‑term trend. The MACD is bullish (0.009 line vs 0.0005 signal) and RSI sits at a neutral 56, while volume is trending upward, suggesting short‑term buying interest may be building.
Recent capital raises ($2.5 M registered direct and private placements) provide runway, and the MGX‑0024 trial claims zero respiratory‑related mortality in large‑scale bird studies, offering a catalyst. Yet the company posts negative revenue growth, a –15.8% operating margin, and no earnings, with a market cap under $8 M and limited liquidity, making the upside speculative and risk‑laden.